Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1092 | 975 | 1157 | 1085 | 1266 | - |
Fund Return | 9.21% | -2.51% | 15.69% | 2.75% | 4.83% | - |
Place in category | 102 | 47 | 289 | 23 | 198 | - |
% in Category | 16 | 9 | 46 | 5 | 43 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
UBS CH Institutional Fund 2 EquiP2X | 9.64B | 24.08 | 6.31 | 11.73 | ||
UBS CH Vitainvest 50 World U | 4.36B | 2.45 | -0.62 | 2.66 | ||
UBS CH Institutional Fund 2 EquiPAX | 4.4B | 20.41 | 4.96 | 9.21 | ||
UBS CH Institutional Fund 2 EquiSCX | 2.83B | 11.68 | -0.82 | 6.98 | ||
UBS CH Institutional Fund 2 EquiSCB | 2.83B | 11.63 | -0.87 | 6.92 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.35B | 9.28 | 2.17 | 6.28 | ||
Raiffeisen Futura Swiss Stock A | 2.13B | 7.92 | -0.59 | 6.39 | ||
UBS CH Equity Fund Swiss Income CHF | 2.06B | 2.43 | 3.56 | 5.81 | ||
UBS CH Equity Fund Swiss Income CHQ | 2.06B | 2.59 | 4.20 | 6.41 | ||
Pictet CH Institutional Swiss EquiZ | 1.69B | 11.68 | 1.93 | 7.71 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novartis | CH0012005267 | 9.54 | 91.93 | -1.87% | |
Roche Holding Participation | CH0012032048 | 9.41 | 253.50 | -0.31% | |
Nestle | CH0038863350 | 9.05 | 75.96 | -0.05% | |
UBS Group | CH0244767585 | 8.20 | 28.35 | +0.18% | |
Zurich Insurance Group | CH0011075394 | 8.04 | 552.00 | -0.18% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Neutral | Buy |
Technical Indicators | Strong Buy | Strong Sell | Strong Buy |
Summary | Strong Buy | Sell | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review